FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease

Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable

Maverick Simulation installs 3D anatomage table at Safdarjung Hospital

The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases

Botanic Healthcare unveils PeptiGlow and LipoLush for beauty and wellness

PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration

WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka

WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030

Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis

Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older

HRV Pharma unveils brand mascots

Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

IMCD unveils future of beauty at In-Cosmetics Latin America 2025

IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends